A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat

OBJECTIVE: We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment-resistant major depressive disorder (TRD) patients in real practice.

METHODS: Nine patients were prescribed NeuropharmagenⓇ for selection of antidepressants for individual patient and their clinical outcomes were followed.

RESULTS: After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients.

CONCLUSION: Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:19

Enthalten in:

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology - 19(2021), 1 vom: 28. Feb., Seite 160-165

Sprache:

Englisch

Beteiligte Personen:

Lee, Kyung Ho [VerfasserIn]
Bahk, Won-Myong [VerfasserIn]
Lee, Soo-Jung [VerfasserIn]
Serretti, Alessandro [VerfasserIn]
Pae, Chi-Un [VerfasserIn]

Links:

Volltext

Themen:

Antidepressive agent
Clinical outcome
Depressive disorder
Journal Article
Treatment
Treatment-resistance

Anmerkungen:

Date Revised 20.04.2022

published: Print

Citation Status PubMed-not-MEDLINE

doi:

10.9758/cpn.2021.19.1.160

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM320704092